We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 44% below its sector, cheaper than its peers on earnings.
Samjin Pharmaceuticals Co., Ltd. is a South Korean company focused on the discovery and development of pharmaceutical products. Their current portfolio includes SA001, a Phase II clinical asset targeting dry eye and Sjögren's syndrome. In the preclinical stage, they are advancing SJP1803/1804 for macular degeneration, alongside SJP601 and SJP1602, which are designed to combat cancer. Additionally, SPJ1604 and SPJ003 are in clinical phases for treating cancer and diabetes. A broader range of candidates, including SJP1901, SJP1902, SJP1801, and SJP006, are undergoing biological testing for potential applications across cancer, fibrosis, cancer immunotherapy, Alzheimer's disease, Parkinson's disease, and anti-viral conditions. The company was founded in 1968 and is based in Seoul, South Korea.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 005500.KS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
